Etiometry Highlights New Study Linking Pre-ECMO IDO2 Trends to Neurologic Outcomes in Infants

BOSTON, Mass. – June 2, 2026 – Etiometry, a leader in AI-driven clinical intelligence, today announced new research published in Pediatric Critical Care Medicine demonstrating that impaired oxygen delivery analytics in the hours leading up to extracorporeal membrane oxygenation (ECMO) were associated with mortality and adverse neurologic outcomes in infants. 

This single-center retrospective cohort study of infants supported on ECMO evaluated the relationship between Etiometry’s inadequate delivery of oxygen index (IDO2) and outcomes in infants requiring ECMO support. Investigators found that higher IDO2 burden in the hours immediately preceding ECMO initiation correlated with worse neurologic and functional outcomes, including electroencephalography abnormalities, abnormal neuroimaging, and mortality. 

The findings add to observational evidence that pre-ECMO physiologic risk trends may be associated with subsequent outcomes and may support further research into clinician review of patient trajectory. The authors noted that elevated IDO2 exposure was associated with worse outcomes in this retrospective infant cohort, supporting future research into how adjunctive oxygen-delivery metrics may inform clinician review.

“This work highlights the importance of understanding a patient’s physiologic trajectory before ECMO,” said Ahmed S. Said, MD, PhD, senior author of the study and pediatric intensivist at Washington University School of Medicine in St. Louis. “Continuous risk analytics such as IDO2 may provide adjunctive information about oxygen-delivery trends for clinician review. Further research is needed to evaluate how these tools may support decision-making in critically ill patients before irreversible neurologic injury occurs. Our goal is to continue investigating how these tools can support clinical review and care-team communication in critically ill patients.”

Etiometry and collaborating investigators are continuing to study the use of physiologic analytics in additional critical care populations, including patients receiving ECMO and mechanical circulatory support (MCS). This work aligns with Etiometry’s broader cardiac solutions strategy to support clinician review of physiologic trends and enhance care-team communication through integrated physiologic data visualization. Ongoing research is evaluating how physiologic trend information may support clinician assessment and situational awareness in defined clinical settings.

About Etiometry

Founded in 2010, Etiometry offers an AI-driven clinical intelligence platform designed to help critical care clinicians make data-driven, proactive decisions. By leveraging advanced analytics and AI-powered insights, the company empowers care teams to detect subtle changes in patient conditions, prevent complications, and improve recovery times.

Etiometry has received 11 FDA clearances and is trusted by leading healthcare institutions worldwide, including top-ranked academic medical centers and pediatric hospitals. The company is committed to advancing patient safety, improving clinical efficiency, and lowering the cost of care through smarter data utilization. To learn more, visit www.etiometry.com.

Media contact:

Samantha Liebhard, Bellmont Partners

samantha@bellmontpartners.com